Breast cancer recurrence rates were similar for postmenopausal women with estrogen receptor-positive DCIS whether they took anastrozole or tamoxifen,...
T-DM1, a HER2-targeted antibody-drug conjugate, improved outcomes for patients with HER2-positive, metastatic breast cancer that had progressed despite prior...
Breast-conserving surgery may be a better option than mastectomy for patients with early-stage breast cancer.
Adding denosumab (Xgeva) to adjuvant aromatase inhibitor therapy improved disease-free survival for postmenopausal women with early-stage hormone receptor-positive breast...
Studies presented at this year’s San Antonio Breast Cancer Symposium shed light on new investigational therapies for patients with...
Guest Post by Kent Osborne, MD Director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine;...
Carlos L. Arteaga, MD, past-president of the AACR, has been selected to receive the 2015 Prize for Scientific Excellence...
Eddy Shih-Hsin Yang, MD, PhD, associate professor and Regional Oncology Active Research (ROAR) Southeast Cancer Foundation Endowed Chair at...
Jamie Holloway, a breast cancer researcher turned breast cancer patient and AACR Scientist↔Survivor Program advocate, started a blog to...
Guest Post by Graham A. Colditz, MD, DrPH Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School...